We observed that oral delivery of the TZD pioglitazone (PIO), an insulin-sensitizer prescribed to patients with prediabetes or existing T2D [11,27,28], counteracted these pathological metabolic outcomes. The gene discussed is INS; the disease is type 2 diabetes mellitus.